CoChat

The human box C/D snoRNAs U3 and U8 are required for pre-rRNA processing and tumorigenesis

Open access
Langhendries, Jean-Louis, Nicolas, Emilien, Doumont, Gilles, Goldman, Serge, Lafontaine, Denis L.J. · 2016 · Oncotarget
Cited by 97

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

// Jean-Louis Langhendries 1 , Emilien Nicolas 1 , Gilles Doumont 3 , Serge Goldman 2, 3 , Denis L.J. Lafontaine 1, 3 1 RNA Molecular Biology, Fonds de la Recherche Scientifique (F.R.S.-FNRS), Université Libre de Bruxelles (ULB), BioPark Campus, Gosselies, Belgium 2 Nuclear Medecine, Erasme Hospital, Université Libre de Bruxelles, Belgium 3 Center for Microscopy and Molecular Imaging (CMMI), BioPark campus, Université Libre de Bruxelles, Belgium Correspondence to: Denis L.J. Lafontaine, email: denis.lafontaine@ulb.ac.be Keywords: snoRNA, nucleolus, ribosome, tumorigenesis, cancer Received: April 11, 2016 Accepted: June 30, 2016 Published: August 09, 2016 ABSTRACT Small nucleolar RNAs (snoRNAs) are emerging as a novel class of proto-oncogenes and tumor suppressors; their involvement in tumorigenesis remains unclear. The box C/D snoRNAs U3 and U8 are upregulated in breast cancers. Here we characterize the function of human U3 and U8 in ribosome biogenesis, nucleolar structure, and tumorigenesis. We show in breast (MCF-7) and lung (H1944) cancer cells that U3 and U8 are required for pre-rRNA processing reactions leading, respectively, to synthesis of the small and large ribosomal subunits. U3 or U8 depletion triggers a remarkably potent p53-dependent anti-tumor stress response involving the ribosomal proteins uL5 (RPL11) and uL18 (RPL5). Interestingly, the nucleolar structure is more sensitive to perturbations in lung cancer than in breast cancer cells. We reveal in a mouse xenograft model that the tumorigenic potential of cancer cells is reduced in the case of U3 suppression and totally abolished upon U8 depletion. Tumors derived from U3-knockdown cells displayed markedly lower metabolic volume and activity than tumors derived from aggressive control cancer cells. Unexpectedly, metabolic tracer uptake by U3-suppressed tumors appeared more heterogeneous, indicating distinctive tumor growth properties that may reflect non-conventional regulatory functions of U3 (or fragments derived from it) in mRNA metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11148

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage

    Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×

    “Use of HCT116 cells expressing p53 or not in an otherwise isogenic background [44], allowed us to further conclude that the involvement of U3 and U8 in processing does not require the presence of p53 (data not shown).”
    Background

Cited by

See all 97

Metadata

Authors
Langhendries, J.-L., Nicolas, E., Doumont, G., Goldman, S., & Lafontaine, D. L. J.
Venue
Oncotarget
Published
2016-08-09
Volume
7
Issue
37
Pages
59519-59534
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2509320946
Cited by
97
References
1
FWCI
3.31
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.